iPhone app draws FDA scrutiny; Synthes founder ponies up $125M for Harvard;

 @FierceMedDev: Roche wins FDA approval for novel diabetes diagnostic. More | Follow @FierceMedDev

 @MarkHFierce: Looks like Panasonic's bid to attract new investment for its healthcare arm is drawing major interest. Story | Follow @MarkHFierce

 @DamianFierce: Intuitive won its first da Vinci lawsuit, dodging $8.5M in damages. Article | Follow @DamianFierce

> Turkey is gearing up to produce its own medical equipment rather than importing the products. Story

> Regulators want to know why Biosense Technologies' iPhone app that lets diabetics check levels of blood, protein and other substances in their urine isn't FDA-cleared for use. Story

> Medical device manufacturer Advant Medical has committed a sizeable investment toward expanding its Galway, Ireland, plant. Story

> Johnson & Johnson ($JNJ) is suing Shasta Technologies, saying the company's logo infringes on its LifeScan unit's trademark. Article

> In a study, Biomet found that patients who received its Oxford Partial Knee implant were 1.8 times more likely than total-knee-replacement recipients to report that their knee felt normal and 2.7 times more likely to be happy with their ability to perform routine tasks. News

> Nephosity won the FDA's OK to start marking an imaging viewing mobile app for diagnostic use. Story   

> Synthes founder Hansjӧrg Wyss has given another $125 million to Harvard to advance the work of The Wyss Institute for Biologically Inspired Engineering, itself launched a few years back from Wyss's initial $125 million gift. Story

Biotech News

 @FierceBiotech: Check out this week's roundup of job changes in biopharma via @MichaelGFierce and @EmilyMFierce. Report | Follow @FierceBiotech

 @JohnCFierce: Aveo shares shellacked after Astellas drops EU game plan on kidney cancer. More | Follow @JohnCFierce

 @RyanMFierce: Merck marks another failure in elusive hunt for Parkinson's disease drugs. Article | Follow @RyanMFierce

> Amid deal frenzy, Elan rejects latest buyout bid from Royalty Pharma. Article

> Pfizer denies knowledge of acquired companies' failures in East German drug trials. Story

> Merck Serono CEO stakes out Boston biotech startups. More

Pharma News

 @FiercePharma: Novo Nordisk figures it could launch Victoza (liraglutide) as obesity treatment by end of 2014. Story | Follow @FiercePharma

 @EricPFierce: Yes, J&J has an impressive pipeline, but its extensions of existing drugs could add billions to the top line. Report | Follow @EricPFierce

> BRIC markets turning out to be tougher to mine than expected. More

> Former Carl Icahn proxy brawler Alex Denner joins fight against Vivus board. Story

> Novartis apologizes over Diovan study as probe shows employee involvement in trials. Article